Cationic peptides neutralize Ox-LDL, prevent its uptake by macrophages, and attenuate inflammatory response

Atherosclerosis

Volumn 236, Issue 1, 2014, Pages

  Aluganti Narasimhulu, Chandrakala ^a   Selvarajan, Krithika ^a   Brown, Matthew ^a   Parthasarathy, Sampath ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Lipid peroxides; Lysine; Modified lipoproteins; Oxidation

Indexed keywords

5F MIMETIC PEPTIDE OF APOA1; ACETYL LOW DENSITY LIPOPROTEIN; ANTIINFLAMMATORY AGENT; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL27; GLYCODELIN DERIVED PEPTIDE; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN; LYSINE; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; ACETYL-LDL; ANTIMICROBIAL CATIONIC PEPTIDE; COPPER; CYTOKINE; GDN PEPTIDE; LL27 PEPTIDE; PEPTIDE; PEPTIDE 5F; PEPTIDE FRAGMENT; PEROXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ELECTROPHORETIC MOBILITY; FOAM CELL; GENE EXPRESSION REGULATION; HEMOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN TRANSPORT; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; C57BL MOUSE; COMPARATIVE STUDY; DRUG EFFECTS; DRUG SCREENING; GENETICS; LIPID PEROXIDATION; METABOLISM; MOLECULAR GENETICS; OXIDATION REDUCTION REACTION; PERITONEUM MACROPHAGE; PERITONITIS; UMBILICAL VEIN ENDOTHELIAL CELL;

AMINO ACID SEQUENCE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; COPPER; CYTOKINES; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MACROPHAGES; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; OXIDATION-REDUCTION; PEPTIDE FRAGMENTS; PEPTIDES; PERITONITIS; PEROXIDASE;

EID: 84905828387     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.06.020     Document Type: Article

References (51)

1. Griendling K.K., Fitzgerald G.A. Oxidative stress and cardiovascular injury: part II: animal and human studies. Circulation 2003, 108:2034-2040.
2. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. JBiol Chem 1997, 272:20963-20966.
3. Pirillo A., Uboldi P., Kuhn H., Catapano A.L. 15-Lipoxygenase-mediated modification of high-density lipoproteins impairs SR-B1 and ABCA1- dependent cholesterol efflux from macrophages. Biochim Biophys Acta 2006, 1761:292-300.
4. Nissen S.E., Taro T., Tuzeu E.M., Schoenhagen P., Cooper C.J., Yasin M., et al. Effect of recombinant apoa1 milano on coronary atherosclerosis in patients with acute coronary syndromes. JAMA 2003, 290(17):2292-2300.
5. Ibanez B., C.Giannarelli G., Cimmino C.G., Santos-Gallego M., Alique A., Pinero G., et al. Recombinant HDL Milano exerts greater anti-inflammatory and plaque stabilizing properties than HDL wild-type. Atherosclerosis 2012, 220(1):72-77.
6. Van Lenten B.J., Navab M., Anantharamaiah G.M., Buga G.M., Reddy S.T., Fogelman A.M. Multiple indications for anti-inflammatory apolipoprotein mimetic peptides. Curr Opin Investig Drugs 2008, 9:1157-1162.
7. Navab M., Anantharamaiah G.M., Reddy S.T., Van Lenten B.J., Fogelman A.M. Apo A-1 mimetic peptides as atheroprotective agents in murine models. Curr Drug Targets 2008, 9:204-209.
8. Bloedon L.T., Dunbar R., Duffy D., Pinell-Salles P., Norris R., DeGroot B.J., et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. JLipid Res 2008, 49:1344-1352.
9. Sherman C.B., Peterson S.J., Frishman W.H. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis. Cardiol Rev 2010, 18:141-147.
10. Mendez A., Anantharamaiah G.M., Segrest J.P., Oram J.F. Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol. JClin Invest 1994, 94:1698-1705.
11. Segrest J.P., De Loof H., Dohlman J.G., Brouillette C.G., Anantharamaiah G.M. Amphipathic helix motif: classes and properties. Proteins 1990, 8:103-117.
12. Davidson W.S., Lund-Katz S., Johnson W.J., Anantharamaiah G.M., Palgunachari M.N., Segrest J.P., et al. The influence of apolipoprotein structure on the efflux of cellular cholesterol to high density lipoprotein. JBiol Chem 1994, 269:22975-22982.
13. Van Lenten B.J., Wagner A.C., Jung C.L., Ruchala P., Waring A.J., Lehrer R.I., et al. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J.Lipid Res 2008, 49:2302-2311.
14. Peterson S.J., D.Husney A.L., Kruger R., Olszanecki F., Ricci L.F., Rodella A., et al. Long-term treatment with the apolipoprotein apolipoprotein A1 mimetic peptide increases antioxidants and vascular repair in type I diabetic rats. JPharmacol Exp Ther 2007, 322:514-520.
15. Mahdavi H., Kim J.B., Safarpour S., Tien D.A., Navab M. Dyslipidemia and cardiovascular diseases. Curr Opin Lipidol 2009, 20:157-158.
16. Su F., Kozaka K.R., Imaizumib S., Gaoa F., Amneusa M.W., Grijalvab V., et al. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. PNAS 2010, 107(46):19997-20002.
17. Buga G.M., Frank J.S., Mottino G.A., Hendizadeh M., Hakhamian A., Tillisch J.H., et al. D-4F decreases brain arteriole inflammation and improves cognitive performance in LDL receptor-null mice on a Western diet. JLipid Res 2006, 47:2148-2160.
18. DeMattos R.B., O'dell M.A., Parsadanian M., Taylor J.W., Harmony J.A., Bales K.R., et al. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U. S. a 2002, 99:10843-10848.
19. Zanetti M. The role of cathelicidins in the innate host defenses of mammals. Curr Issues Mol Biol 2005, 7:179-196.
20. Yang D., Chen Q., Schmidt A.P., Anderson G.M., Wang J.M., Wooters J., et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemo attracts human peripheral blood neutrophils, monocytes, and T-cells. JExp Med 2000, 192:1069-1074.
21. Davidson D.J., Currie A.J., Reid G.S., Bowdish D.M., MacDonald K.L., Ma R.C., et al. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. JImmunol 2004, 172:1146-1156.
22. Koczulla R., von Degenfeld G., Kupatt C., Krotz F., Zahler S., Gloe T., et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. JClin Invest 2003, 111:1665-1672.
23. Shaykhiev R., Beisswenger C., Kaendler K., Senske J., Puechner A., Damm T., et al. The human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure. Am J Physiol Lung Cell Mol Physiol 2005, 289:842-848.
24. Tjabringa G.S., Aarbiou J., Ninaber D.K., Drijfhout J.W., Sorensen O.E., Borregaard N., et al. The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. JImmunol 2003, 171:6690-6696.
25. Nagaoka I., Hirota S., Niyonsaba F., Hirata M., Adachi Y., Tamura H., et al. Cathelicidin family of antibacterial peptides CAP18 and CAP11 inhibit the expression of TNF-alpha by blocking the binding of LPS to CD14 cells. JImmunol 2001, 167:3329-3338.
26. Busch S., Belting M. The human antimicrobial peptide LL-37 transfers extracellular DNA plasmid to the nuclear compartment of mammalian cells via lipid rafts and proteoglycan-dependent endocytosis. JBiol Chem 2004, 279:17951-17956.
27. Julkunen M., Seppälä M., Jänne O.A. Complete amino acid sequence of human placental protein 14: a progesterone-associated uterine protein homologous to β-lactoglobulins. Proc Natl Acad Sci U S A 1988, 85:8845-8849.
28. Richlin S.S., Ramachandran S., Shanti A., Murphy A.A., Parthasarathy S. Glycodelin levels in uterine flushings and in plasma of patients with leiomyomas and polyps: implications for implantation. Hum Reprod 2002, 17:2742-2747.
29. Seppälä M., Taylor R.N., Koistinen H., Koistinen R., Milgrom E. Glycodelin: a major lipocalin protein of the reproductive axis with diverse actions in cell recognition and differentiation. Endocr Rev 2002, 23:401-430.
30. Fruebis J., Parthasarathy S., Stienberg D. Evidence for a concerted reaction between lipid hydroperoxides and polypeptides. Proc Nati. Acad Sci USA 1992, 89:10588-10592.
31. Santanam N., Parthasarathy S. Paradoxical actions of antioxidants in the oxidation of low density lipoprotein by peroxidases. JClin Invest 1995, 95:2594-2600.
32. Auerbach B.J., Kiely J.S., Cornicelli J.A. Aspectrophotometric microtiter-based assay for the detection of hydroperoxy derivatives of linoleic acid. Anal Biochem 1992, 201(2):375-380.
33. Fraenkel-Conrat H. Methods for investigating the essential groups for enzyme activity. Methods Enzymol 1957, 4:247.
34. Khan-Merchant N., Penumetcha M., Meilhac O., Parthasarathy S. Oxidized fatty acids promote atherosclerosis only in the presence of dietarycholesterol in low-density lipoprotein receptor knockout mice. JNutr 2002, 132:3256-3262.
35. Chandrakala A.N., Sukul D., Selvarajan K., Sai-Sudhakar C., Sun B., Parthasarathy S. Induction of brain natriuretic peptide and monocyte chemotactic protein-1 gene expression by oxidized low-density lipoprotein: relevance to ischemic heart failure. Am J Physiol Cell Physiol 2012, 302:C165-C177.
36. Kyte J., Doolittle R.F. Asimple method for displaying the hydrophobic character of a protein. JMol Bwl 1982, 157:105-132.
37. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. NEngl J Med 1989, 320:915-924.
38. Parthasarathy S., Fong L.G., Otero D., Steinberg D. Recognition of solubilized apoproteins from delipidated, oxidized low density lipoprotein (LDL) by the acetyl-LDL receptor. Proc Natl Acad Sci U S A 1987, 84:537-540.
39. Dai L., Datta G., Zhang Z., Gupta H., Patel R., Honavar J., et al. The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic rats. JLipid Res 2010, 51:2695-2705.
40. Navab M., Hama S.Y., Anantharamaiah G.M., Hassan K., Hough G.P., Watson A.D., et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. JLipid Res 2000, 41:1495-1508.
41. Panzenbock U., Stocker R. Formation of methionine sulfoxide- containing specific forms of oxidized high-density lipoprotein. Biochim Biophys Acta 2005, 1703:171-181.
42. Lim Y.S., Cha M.K., Kim H.K., Uhm T.B., Park J.W., Kim k., et al. Removals of hydrogen peroxide and hydroxyl radical by thiol-specific antioxidant protein as a possible role invivo. Biochem Biophys Res Commun 1993, 192:273-280.
43. Kadoma Y., Fujisawa S. Radical-scavenging activity of dietary Phytophenols in combination with co-antioxidants using the induction. Period Method Mol 2011, 16:10457-10470.
44. Hancock R.E., Scott M.G. The role of antimicrobial peptides in animal defense. Proc Natl Acad Sci U S A 2000, 97:8856-8861.
45. Cohen J. The immunopathogenesis of sepsis. Nature 2002, 420:885-891.
46. Larrick J.W., Hirata M., Balint R.F., Lee J., Zhong J., Wright S.C. Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect Immun 1995, 63:1291-1297.
47. Brown K.L., Poon G.F., Birkenhead D., Pena O.M., Falsafi R., Dahlgren C., et al. Host defense peptide LL-37 Selectively reduces Pro-inflammatory macrophage responses. JImmunol 2011, 186:5497-5505.
48. Scott A., Weldon S., Bauchanan P.J., Schock B., Ernst R.K., AcAuley D.F., et al. Evaluation of the ability of LL-37 to neutralize LPS invitro and exvivo. PLosOne 2011, 6(10):e26525.
49. Gupta H., Dai L., Datta G., Garber D.W., Grenett H., Li Y., et al. Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide. Circ Res 2005, 97:236-243.
50. Edfeldt K., Agerberth B., Rottenberg M.E., Gudmundsson G.H., Wang X., Mandal K., et al. Involvement of the antimicrobial peptide LL-37 in human atherosclerosis. Arterioscler Thromb Vasc Biol 2006, 26:1551-1557.
51. Döring Y., Drechsler M., Wantha S., Kemmerich K., Lievens D., Vijayan S., et al. Lack of Neutrophil-derived CRAMP reduces atherosclerosis in mice. Circulation Res 2012, 110:1052-1056.